Fidelity Select Portfolios - Medical Technology and Devices Portfolio
FSMEX
NASDAQ- -
USD
- -
- -
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Sector
- Financial Services
- Industry
- Asset Management
- Address
- 245 Summer Street Boston MA United States of America 2210
- IPO Date
- Apr 28, 1998
- CIK
- 0000320351
- Website
- fundresearch.fidelity.com
- Similar Companies
- Business
- Fidelity Select Medical Technology and Devices Portfolio (FSMEX) is an open-end mutual fund managed by Fidelity Investments that seeks capital appreciation by investing primarily in securities of companies engaged in the research, development, manufacture, distribution, supply, or sale of medical equipment, devices, and related technologies; companies enabling drug discovery; and companies providing information technology services primarily to healthcare providers. The fund normally invests at least 80% of its assets in common stocks of such issuers, including domestic and foreign companies, and is non-diversified with a portfolio concentrated in the healthcare sector, particularly medical technology and devices, holding approximately 66 securities with top positions in Boston Scientific Corp., Danaher Corp., Thermo Fisher Scientific Inc., Intuitive Surgical Inc., and Stryker Corp. It features a net expense ratio of 0.63%, no minimum initial investment, semi-annual dividends, and a turnover rate of 31%, with assets under management of approximately $4.24 billion as of recent data. Launched on April 28, 1998, and headquartered in Boston, Massachusetts, the fund operates within the U.S. domiciled market, focusing on mid-cap blend style stocks in the health category and primarily targeting U.S. investors seeking exposure to the medical technology segment of the healthcare industry. Fidelity Investments serves as the fund family and manager, with Edward Yoon leading the portfolio since May 1, 2007. The fund maintains a focus on its core investment mandate without reported major structural changes, such as acquisitions, partnerships, funding rounds, name changes, or reorganizations in the last 1-2 years. Recent performance highlights include a 5-year annualized return of approximately 19.81% and a Zacks Mutual Fund Rank of 2 (Buy) as of December 2025, reflecting its competitive positioning despite modest recent returns. No new product launches or significant strategic shifts have been noted in public disclosures.